A Phase 1 interventional study of AZD0780 tablet and [14C]AZD0780 Solution for Infusion in Cardiovascular Diseases, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-11.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The Sponsor is developing a new test medicine, AZD0780, with the aim to lower low-density lipoprotein cholesterol (LDL-C, fatty deposits) levels and cardiovascular (heart disease) risk, when given on top of standard care.
This two-part healthy volunteer study will try to identify how the test medicine is taken up, broken down and removed from the body. To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14; also referred as 14C) which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.
This study will take place at one non-NHS site, enrolling up to 8 male volunteers aged between 30 and 55 years.
The Sponsor is developing a new test medicine, AZD0780, with the aim to lower low-density lipoprotein cholesterol (LDL-C, fatty deposits) levels and cardiovascular (heart disease) risk, when given on top of standard care. High levels of LDL-C can build up on the walls of blood vessels, forming plaques which can increase the risk of heart disease and stroke.
This two-part healthy volunteer study will try to identify how the test medicine is taken up, broken down and removed from the body.
To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14; also referred as 14C) which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.
This study will take place at one non-NHS site, enrolling up to 8 male volunteers aged between 30 and 55 years.
In Part 1, volunteers will receive a single oral dose of AZD0780 on Day 1. The volunteers will then receive a single intravenous dose of [14C]AZD0780, 2.25 hours after the oral dose. Volunteers will be discharged on Day 8. Following a minimum 14 day washout period, all volunteers who participated in Part 1 of the study will be admitted to the clinical unit for Part 2. In Part 2, the volunteers will receive a single oral dose of [14C]AZD0780 on Day 1. Volunteers will be discharged on Day 11, however, if relevant radioactivity criteria have not been met, volunteers may need to remain at the clinical unit until Day 13. If relevant criteria have not been met at this point, home collections of urine and/or faeces may be required.
Volunteers will receive a follow up phone call between Day 18 and 21.
Volunteer's blood and urine and faeces will be taken throughout the study for analysis of the test medicine and for their safety.
Volunteers are expected to be involved in this study for 10 weeks from screening to the follow up call.
5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.
This study's enrollment of 8 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part 1, one oral dose of AZD0780 and one intravenous dose of \[14C\]AZD0780. In Part 2, one oral dose of \[14C\]AZD0780
Drug: AZD0780 tablet · Drug: [14C]AZD0780 Solution for Infusion · Drug: [14C]AZD0780 Oral Solution
oral, fasted
Also known as: AZD0780
intravenous
Also known as: [14C]AZD0780
oral, fasted
Also known as: [14C]AZD0780
Absolute bioavailability (F) - Part 1
Absolute bioavailability based on AUC0-inf of oral formulation compared to IV adjusted for dose
Time frame: Plasma sample collection from pre-dose to 168 hours post-dose
Area under the curve from time 0 extrapolated to infinity for AZD0780 and total radioactivity (AUC0-inf) - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
Time to maximum concentration (tmax) for AZD0780 and total radioactivity - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
Maximum observed concentration (Cmax) for AZD0780 and total radioactivity - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
Area under the curve from time 0 to the time of last measurable concentration for AZD0780 and total radioactivity (AUC0-t) - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUCextrap) and total radioactivity - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
Terminal elimination half-life for AZD0780 (t1/2) and total radioactivity - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
First order rate constant associated with the terminal (log-linear) portion of the curve for AZD0780 (λz) and total radioactivity - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
Total body clearance calculated after a single IV administration (CL) - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F) - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
Volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single IV administration (Vz) - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
Volume of distribution at steady state after a single IV administration (Vss) - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
Apparent volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F) - Part 1
PK of AZD0780 and \[14C\]AZD0780 in plasma
Time frame: Plasma sample collection from pre-dose until 168 hours post-dose
Amount of AZD0780 excreted (Ae) - Part 2
Mass balance of total radioactivity (TR) of \[14C\]AZD0780 in urine and faecal samples
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Amount of AZD0780 excreted expressed as a fraction of dose excreted (%Ae) - Part 2
Mass balance of total radioactivity (TR) of \[14C\]AZD0780 in urine and faecal samples
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
The cumulative amount of AZD0780 exreted (CumAe) - Part 2
Mass balance of total radioactivity (TR) of \[14C\]AZD0780 in urine and faecal samples
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Cumulative amount of AZD0780 excreted expressed as a fraction of dose excreted (Cum%Ae) - Part 2
Mass balance of total radioactivity (TR) of \[14C\]AZD0780 in urine and faecal samples
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Time to maximum concentration (tmax) for AZD0780 and total radioactivity - Part 2
PK of AZD0780 in urine and faeces
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Maximum observed concentration (Cmax) for AZD0780 and total radioactivity - Part 2
PK of AZD0780 in urine and faeces
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Area under the curve from time 0 to the time of last measurable concentration for AZD0780 and total radioactivity (AUC0-t) - Part 2
PK of AZD0780 in urine and faeces
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Area under the curve from time 0 extrapolated to infinity for AZD0780 and total radioactivity (AUC0-inf) - Part 2
PK of AZD0780 in urine and faeces
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUCextrap) and total radioactivity - Part 2
PK of AZD0780 in urine and faeces
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Terminal elimination half-life for AZD0780 (t1/2) and total radioactivity - Part 2
PK of AZD0780 in urine and faeces
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
First order rate constant associated with the terminal (log-linear) portion of the curve for AZD0780 (λz) and total radioactivity - Part 2
PK of AZD0780 in urine and faeces
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F) - Part 2
PK of AZD0780 in urine and faeces
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Apparent volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F) - Part 2
PK of AZD0780 in urine and faeces
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Renal clearance calculated using plasma AUC (CLR) - Part 2
PK of AZD0780 in urine and faeces
Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose
Number of subjects with treatment-related adverse events - Part 1 and Part 2
To provide additional safety and tolerability information for AZD0780 by assessing the incidence of AEs
Time frame: Through study duration, an average of 10 weeks
Blood:plasma concentration ratios - Part 2
Blood:plasma concentration ratios of total radioactivity
Time frame: Whole blood samples and plasma samples collected from pre-dose until 240 hours post-dose
Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating TR (plasma) or accounting for 10% or more of the dose in urine and faeces - Part 2
Metabolite profiling and structural identification from plasma, urine and faecal samples. Metabolites are to be reported in a separate report after the Clinical Study Report is final.
Time frame: Plasma, urine and faecal samples collected from pre-dose until 240 hours post-dose
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Apr 2023 to primary completion in Jun 2023, 1 month.
Of 53 industry-sponsored phase 1 interventional studies under Cardiovascular Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's 1 month is below that.
Counting every sponsor, half of 96 studies reached it within 15 months; a quarter within 3 and three quarters within 45.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Laroprovstat